HRP20192230T1 - Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita - Google Patents

Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita Download PDF

Info

Publication number
HRP20192230T1
HRP20192230T1 HRP20192230TT HRP20192230T HRP20192230T1 HR P20192230 T1 HRP20192230 T1 HR P20192230T1 HR P20192230T T HRP20192230T T HR P20192230TT HR P20192230 T HRP20192230 T HR P20192230T HR P20192230 T1 HRP20192230 T1 HR P20192230T1
Authority
HR
Croatia
Prior art keywords
pharmacological agent
tat
peptide
intended
mast cell
Prior art date
Application number
HRP20192230TT
Other languages
English (en)
Croatian (hr)
Inventor
Michael Tymianski
Jonathan David Garman
Hong Cui
Original Assignee
Nono Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nono Inc. filed Critical Nono Inc.
Publication of HRP20192230T1 publication Critical patent/HRP20192230T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20192230TT 2009-06-10 2010-06-10 Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita HRP20192230T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18594309P 2009-06-10 2009-06-10
EP10786870.5A EP2440231B1 (en) 2009-06-10 2010-06-10 Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor
PCT/US2010/038226 WO2010144742A2 (en) 2009-06-10 2010-06-10 Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Publications (1)

Publication Number Publication Date
HRP20192230T1 true HRP20192230T1 (hr) 2020-03-20

Family

ID=43309471

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20192230TT HRP20192230T1 (hr) 2009-06-10 2010-06-10 Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita

Country Status (16)

Country Link
US (4) US8933013B2 (https=)
EP (2) EP3682895A1 (https=)
JP (5) JP5886192B2 (https=)
AU (1) AU2010259986B2 (https=)
CA (2) CA2765171C (https=)
CY (1) CY1122584T1 (https=)
DK (1) DK2440231T3 (https=)
ES (1) ES2765281T3 (https=)
HR (1) HRP20192230T1 (https=)
HU (1) HUE046640T2 (https=)
LT (1) LT2440231T (https=)
PL (1) PL2440231T3 (https=)
PT (1) PT2440231T (https=)
SI (1) SI2440231T1 (https=)
SM (1) SMT202000056T1 (https=)
WO (1) WO2010144742A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
DK2320927T3 (en) * 2008-07-09 2015-09-14 Univ Copenhagen Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
EP3682895A1 (en) 2009-06-10 2020-07-22 NoNO Inc. Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor
PH12012500565B1 (en) 2009-09-22 2018-01-12 Medicago Inc Method of preparing plant-derived proteins
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
ES2912042T3 (es) 2011-06-24 2022-05-24 Nono Inc Terapia de combinación para isquemia
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
CA2892965C (en) * 2012-11-28 2021-06-01 Nono Inc. Lyophilized formulation of tat-nr2b9c
WO2016172219A1 (en) * 2015-04-24 2016-10-27 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for inhibition of toll-like receptors (tlrs)-mediated inflammation
AU2016382134B2 (en) 2015-12-28 2022-09-22 Idemitsu Kosan Co., Ltd. Peptide tag and tagged protein including same
KR102403089B1 (ko) * 2017-07-05 2022-06-02 바이오셀즈(베이징) 바이오테크 코., 엘티디. 폴리펩타이드의 약학적으로 허용 가능한 염 및 이의 용도
HRP20250272T1 (hr) 2017-10-19 2025-04-25 Teijin Pharma Limited Derivati benzimidazola i njihova uporaba
US20230055441A1 (en) * 2020-01-09 2023-02-23 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
US20240301003A1 (en) 2021-01-08 2024-09-12 Nono Inc. Plasmin-resistant peptides for improved therapeutic index

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316003B1 (en) 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
EP1159418A2 (en) 1998-12-11 2001-12-05 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
US20040226056A1 (en) 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US20060148711A1 (en) 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
DE60026313D1 (de) 1999-07-23 2006-04-27 Uutech Ltd Sensibilisierung von roten blutkörperchen gegenüber ultraschall durch einwirkung eines elektrischen feldes
CA2381425A1 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20020032154A1 (en) 2000-06-07 2002-03-14 Peyman John A. Interferon-suppressing placental lactogen peptides
US6887687B2 (en) 2001-07-30 2005-05-03 Immunex Corporation Nucleic acids encoding human ataxin-1-like polypeptide IMX97018
WO2004045535A2 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons
EP1601380A1 (en) 2003-02-13 2005-12-07 Licentia OY Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
US20050256065A1 (en) * 2004-01-26 2005-11-17 Permasight Method for stabilizing changes in corneal curvature in an eye by administering compositions containing stabilizing ophthalmic agents
US7151084B2 (en) 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
KR101384572B1 (ko) 2005-12-30 2014-04-24 아버 비타 코포레이션 Ｐｄｚ 상호작용의 소형 분자 억제제
DK2043671T3 (da) * 2006-07-11 2020-06-15 Nono Inc Peptid og sammensætning deraf til anvendelse ved behandling af slagtilfælde med feber
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
ES2446292T3 (es) 2007-03-02 2014-03-07 Nono Inc. Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
WO2009006611A1 (en) 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
CN101842107B (zh) 2007-07-26 2014-04-23 雷文斯治疗公司 抗微生物肽，组合物和使用方法
ES2328776B1 (es) 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
DK2320927T3 (en) 2008-07-09 2015-09-14 Univ Copenhagen Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
EP3682895A1 (en) * 2009-06-10 2020-07-22 NoNO Inc. Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor

Also Published As

Publication number Publication date
LT2440231T (lt) 2020-01-10
US20170043030A1 (en) 2017-02-16
EP2440231A2 (en) 2012-04-18
HUE046640T2 (hu) 2020-03-30
JP5886192B2 (ja) 2016-03-16
CA3018494C (en) 2021-12-07
EP2440231A4 (en) 2013-04-24
DK2440231T3 (da) 2020-01-13
EP2440231B1 (en) 2019-12-04
JP2020125328A (ja) 2020-08-20
PL2440231T3 (pl) 2020-05-18
CA2765171C (en) 2018-10-02
US20190038760A1 (en) 2019-02-07
JP2012530060A (ja) 2012-11-29
JP6775478B2 (ja) 2020-10-28
SMT202000056T1 (it) 2020-03-13
EP3682895A1 (en) 2020-07-22
ES2765281T3 (es) 2020-06-08
SI2440231T1 (sl) 2020-08-31
JP7209364B2 (ja) 2023-01-20
JP2018030859A (ja) 2018-03-01
JP2023017813A (ja) 2023-02-07
US20150126460A1 (en) 2015-05-07
US9433685B2 (en) 2016-09-06
CA3018494A1 (en) 2010-12-16
AU2010259986A1 (en) 2012-01-12
US10046060B2 (en) 2018-08-14
US20120252731A1 (en) 2012-10-04
JP2016000735A (ja) 2016-01-07
PT2440231T (pt) 2020-01-08
JP6238934B2 (ja) 2017-11-29
AU2010259986B2 (en) 2015-04-02
WO2010144742A2 (en) 2010-12-16
US8933013B2 (en) 2015-01-13
CY1122584T1 (el) 2021-01-27
WO2010144742A3 (en) 2011-04-21
CA2765171A1 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
HRP20192230T1 (hr) Suprimjena sredstva spojenog s peptidom za internaliziranje tat s inhibitorom degranuliranja mastocita
JP2012530060A5 (https=)
ES2685505T3 (es) Inhibidor de cinasas basado en péptidos de permeación celular
ES2879550T3 (es) Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares.
JP2023002662A5 (https=)
CA2829101C (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
JP2013543492A5 (https=)
RU2013127565A (ru) Ингибиторы апоптоза и их применение
WO2011047097A3 (en) Inhibition of trem receptor signaling with peptide variants
ES2523659T3 (es) Composiciones y procedimientos para el tratamiento de enfermedades cardiovasculares
BRPI0914504B1 (pt) uso de um peptídeo intestinal vasoativo (piv) ou um ou mais fragmentos funcionais do piv
ES2523858T3 (es) Fragmentos de VIP y composiciones de los mismos
EP3820470B1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators for use in treating portal hypertension
CN113735938B (zh) 一种神经保护多肽化合物及其应用
CN105451756A (zh) 在治疗马凡氏综合征及其相关病症中的血管紧张素肽
JP2009500045A5 (https=)
CN111032055A (zh) 使用胰高血糖素样肽2的下尿路上皮的治疗
WO2020055226A1 (es) Combinación farmacéutica sinérgica de un inhibidor selectivo de la ciclooxigenasa 2 y un derivado de antraquinona
JP5477794B2 (ja) エンドキニンｃ／ｄ由来のペプチド
Zhang et al. Efficacy and safety of combination of magnesium sulfate, phentolamine and nifedipine in treatment of patients with hypertensive disorder complicating pregnancy
CN104524544B (zh) 一种多肽在治疗糖尿病中的应用
Wang et al. Loganin epigenetically rescues mitochondrial complex III dysfunction via DNMT1-UQCRC1 demethylation to halt cardiac remodeling after myocardial infarction
JP2014512369A5 (https=)
CA3088576C (en) COMPOSITION INTENDED FOR THE TREATMENT OF A PATIENT SUFFERING FROM ULCERATIVE COLITIS AND USE OF THE COMPOSITION AS A MEDICINE
RU2018125958A (ru) Селективные агонисты рецептора глюкагона, содержащие хелатообразующий фрагмент, для целей визуализации